The Haunting of Medical Journals: How Ghostwriting Sold “HRT”
article has not abstract
Vyšlo v časopise:
The Haunting of Medical Journals: How Ghostwriting Sold “HRT”. PLoS Med 7(9): e32767. doi:10.1371/journal.pmed.1000335
Kategorie:
Policy Forum
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000335
Souhrn
article has not abstract
Zdroje
1. Fugh-BermanA
ScialliAR
2006 Gynecologists and estrogen: an affair of the heart. Perspect Biol Med 49 115 130
2. HulleyS
GradyD
BushT
FurbergC
HerringtonD
1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 605 613
3. RossouwJE
AndersonGL
PrenticeRL
LaCroixAZ
KooperbergC
2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321 333
4. The Women's Health Initiative Steering Committee 2004 Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 291 1701 1712
5. ShumakerSA
LegaultC
KullerL
RappSR
ThalL
2004 Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 2947 2958
6. HendrixSL
CochraneBB
NygaardIE
HandaVL
BarnabeiVM
2005 Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 935 948
7. PowerML
AndersonBL
SchulkinJ
2009 Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause 16 500 508
8. PowerML
BaronJ
SchulkinJ
2008 Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy. Med Decis Making 28 411 418
9. Fugh-BermanA
DodgsonS
2008 The ethics of publication planning in the pharmaceutical industry. Open Medicine 2 4 e33 6
10. MathesonAlastair
2008 Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry. Biosocieties 3 355 82
11. Fugh-BermanA
2005 The corporate coauthor. J Gen Intern Med 20 546 548
12. SismondoS
2007 Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4 e286
13. LAWT203-0000254-0000266 at LAWT203-0000255 (DesignWrite Powerpoint. Expanding Choices. 2003 Strategic Publications Plan for Women's Health Care. November 22, 2002). Available: http://dida.library.ucsf.edu/tid/ssb37b10. Accessed 21 Aug 2009
14. DesignWrite [Internet] Princeton, , NJ Jobson Healthcare Information LLC, c1997- 2009. Available: http://www.jmihealth.com/marketing- communication/communication/designwrite.php. Accessed 15 Aug 2009
15. DWRITE065923 (The 1997 Premarin Publication Program) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/juc37b10. Accessed 21 Aug 2009
16. Mittleman5022006 at 188:8–188:10, 190–91; 214; 221; 222; 223–4. May 2, 2006 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/zkb37b10. Accessed 21 Aug 2009
17. DWRITE019241 at DWRITE019242 (Continuing Medical Education in Women's Health Care Proposal for 2004 satellite symposia) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/iwb37b10. Accessed 21 Aug 2009
18. STRIS014-000675 (HOPE Trial Publication Plan Proposal Year 1 Data) [Internet] San Francisco Drug Industry Document Archive 2000. Available: http://dida.library.ucsf.edu/tid/wqc37b10. Also DWRITE066150 at DWRITE066150 and DWRITE066152 (2003 Publication Plan). Available: http://dida.library.ucsf.edu/tid/kic37b10. Other supporting documentation: DWRITE066162 Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 15 Feb 2010
19. DELCA031-019050 and DELCA031-019052-019068 (Endometrial Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate); DELCA004-001404 and DELCA004-001405-001432 (Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Vasomotor Symptoms and Vaginal Atrophy); DELCA032-028548 and DELCA032-028549-028569 (Effects of Lower Doses of Conjugated Estrogens and Medroxyprogesterone Acetate on Plasma Lipids and Lipoproteins, Coagulation Factors, and Carbohydrate Metabolism); MARTN010-003367 and MARTN010-003371; MARTN010-003512 and MARTN010-003513-003535 (Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate on Endometrial Bleeding) [Internet] San Francisco Drug Industry Document Archive c2008. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
20. STRIS014-000675 (HOPE Trial Publication Plan Proposal Year 1 Data). Other supporting documentation: PICKJ038-000119 and PICKJ042-004545; PICKJ038- 000071 and PICKJ038-000065; STRIS014-000674. [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
21. DWRITE065950 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jwb37b10. (Note: on this and some of the other documents produced by DesignWrite, the date appearing on the document is inaccurate, reflecting the date the documents were copied by DesignWrite for production to Plaintiffs, not the date the document was actually created. See discussion at Mittleman5022006 at 127–132, May 2, 2006.) Accessed 21 Aug 2009
22. DWRITE065764 at DWRITE065775 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jrb37b10. Accessed 21 Aug 2009
23. DWRITE066095 at DWRITE066097 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/kgb37b10. Accessed 21 Aug 2009
24. GRUBG001-021895-21902 at GRUBG001-021900 (Premarin/TMG 300-US Publication Plan Proposal. DesignWrite 2003) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/sac37b10. Accessed 21 Aug 2009
25. CONTA025-020958 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/bec37b10. Accessed 21 Aug 2009
26. Solomon_01262006, January 26, 2006 at 317:14–15 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/woc37b10. Accessed 21 Aug 2009
27. Solomon_01272006, January 27, 2006 at 397:22; 398:10 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/wpb37b10. Accessed 21 Aug 2009
28. DWRITE076707 (Also see DWRITE066958) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/rib37b10 and http://dida.library.ucsf.edu/tid/loc37b10. Accessed 21 Aug 2009
29. BalterW
SkeltonM
SafirPO
2003 The P's and Q's of publication planning. Pharm Executive May 130 6
30. Fugh-BermanA
MelnickD
2008 Off-label promotion, on-target sales. PLoS Med 5 e210
31. CONTA023-006750 (Publication Planning and Management slideshow) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/atb37b10. Accessed 21 Aug 2009
32. CONTA023-007214 (Setting the Scientific Agenda slideshow) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/atc37b10. Accessed 21 Aug 2009
33. DESIGN052780-DESIGN052781 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/duc37b10. Accessed 21 Aug 2009
34. DESIGN177338 (E-mail correspondence between Karen Mittleman and Sandra Leiblum) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/exb37b10. Accessed 21 Aug 2009
35. DESIGN024396 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/djb37b10. Accessed 21 Aug 2009
36. DESIGN024724 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/dkb37b10. Accessed 21 Aug 2009
37. DESIGN024526 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/djc37b10. Accessed 21 Aug 2009
38. DWRITE066498 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/kub37b10. Accessed 21 Aug 2009
39. DESIGN175720 at DESIGN175721 and DESIGN175722 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/ewb37b10. Accessed 21 Aug 2009
40. STRIS016-031138 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/wsc37b10. Accessed 21 Aug 2009
41. DESIGN010191-010204 at DESIGN010193 (Trimegestone –Publication and Abstract Tracking Report) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/dfc37b10. Accessed 21 Aug 2009
42. DWRITE065764 at DWRITE065770 (Medical Education and Communication Plan for the Premarin Product Line. Submitted by DesignWrite, Inc., Aug 12, 1996) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/zqc37b10. Accessed 21 Aug 2009
43. CONTA025-031623 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/boc37b10. Accessed 21 Aug 2009
44. DESIGN170355 (E-mail from Gerald Burr, October 11, 1999) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/elb37b10. Accessed 21 Aug 2009
45. DESIGN170356-170394, DESIGN170395-170418, DESIGN170419-170468, DESIGN170469-170498 and DESIGN170499-170528 [Internet]. Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
46. DWRITE068884- DWRITE06895 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/pdf/opc37b10. Accessed 21 Aug 2009
47. PCSAR001-000927 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/vpc37b10. Other supporting documentation: DESIGN018080. Available: http://dida.library.ucsf.edu/tid/dhc37b10. DESIGN018239. Available: http://dida.library.ucsf.edu/tid/dic37b10. DWRITE079093 Available: http://dida.library.ucsf.edu/tid/ruc37b10; DWRITE068320. Available: http://dida.library.ucsf.edu/tid/oib37b10; CONSG204-024407. Available: http://dida.library.ucsf.edu/tid/arc37b10 [Internet]. San Francisco: Drug Industry Document Archive. Accessed 15 Feb 2010
48. DWRITE066543 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/lcc37b10. Accessed 21 Aug 2009
49. DWRITE065858 at DWRITE065859 (Strategic Competitive Intelligence on the HRT Market: A source document. Speakers Bureau Meeting) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jtb37b10. Accessed 21 Aug 2009
50. ThorneycroftIH
2001 Prevention of Heart Disease in Women: Is Postmenopausal Estrogen Therapy Warranted? (Point-Counterpoint) The HERS Trial Does Not Confute a Cardioprotective Effect of Hormone Therapy. Menopause Management. July/Aug; 16–28
51. MoscaL
2000 Hormone Replacement Therapy in the Prevention and Treatment of Atherosclerosis. Current Atherosclerosis Reports 2 4 297 302
52. DWRITE066162 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/kjb37b10. Accessed 21 Aug 2009
53. BrincatM
BaronY
GaleaR
2005 Estrogens and the skin. Climacteric 8 2 110 123
54. BachmanG
LeiblumS
2004 The Impact of Hormones on Menopausal Sexuality: aLiterature Review. Menopause 11 1 120 130
55. EdenJ
2003 May Progestins and breast cancer. Am J Obstet Gynecol 188 5 1123 31 [This article was cited in a staff report for the U.S. Senate Committee on Finance as one of the “examples of articles that Wyeth had paid the medical communications firm, DesignWrite, to outline and draft for target authors.” U.S. Sen. Comm. on Finance, Minority Staff Report, Ghostwriting in Medical Literature at 4 & n.6 (June 24, 2010). In a letter to Wyeth cited in the staff report, U.S. Senator Charles Grassley also noted that the article did “not identify the original author.” In a judicial opinion published in late 2009, the U.S. Court of Appeals for the Eighth Circuit identified the Eden article as one of the “ghost written articles” commissioned by Wyeth. Scroggin v. Wyeth (In re: Prempro Products Liability Litigation), 586 F.3d 547, 557 (8th Cir. 2009) (“In 2000, Wyeth tapped Dr. John Eden to author ‘Breast Cancer and Progestins,’ but the true author was a technical writing company, hired to produce the manuscript for Wyeth's approval and Dr. Eden's editing.”). Earlier this year, however, the publisher of the American Journal of Obstetrics and Gynecology informed Dr. Eden that, after conducting an investigation, it did not believe the article was ghostwritten. ]
56. CONTA025-030538 (Strategic Publications Development Meeting June 15, 2000 Meeting Recap) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/bob37b10. Accessed 21 Aug 2009
57. DWRITE003353 (Project Assignment Form) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/ifc37b10. Accessed 21 Aug 2009
58. DWRITE065923 at DWRITE065927 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/juc37b10. Accessed 21 Aug 2009
59. CurtisM
1999 Selective Estrogen Receptor Modulators: A Controversial Approach for Managing Postmenopausal Health. J Women's Health 8 3 321 33
60. DUROJ023-001712 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/ghb37b10. Accessed 21 Aug 2009
61. CurtisMG
2001 Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention. Drug Safety 2001;24 14 1039 53
62. AnsbacherR
2001 The Pharmacokinetics and Efficacy of Different Estrogens are Not Equivalent. Am J Obstet Gynecol 184 3 255 63
63. WarrenM
2004 A Comparative Review of the Risks and Benefits of Hormone Replacement Therapy Regimens. Am J Obstet Gynecol 190 4 1141 67
64. CONSG204-015605 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/arb37b10. Accessed 21 Aug 2009
65. DWRITE065923 at DWRITE065931 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/juc37b10. Accessed 21 Aug 2009
66. Janas_010408 at 385:18–24; DWRITE001229 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
67. Janas_010408 at 388: 19–24, 389: 1–6, 392: 6–24 and 393: 1–16 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
68. DWRITE001927 and Janas_010408 at 418: 8–13 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/hmc37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
69. Janas_010408 at 461: 7–21 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
70. DWRITE001904 and Janas_010408 at 397: 4–15 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/hmb37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
71. DWRITE001894 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/hlc37b10. Accessed 21 Aug 2009
72. Janas_010408 at 406:14–23 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
73. DWRITE040906 through DWRITE040938, specifically DWRITE040932 (Exh. 91 to Janas Depos.); Janas_010408 at 471:24–472:3 and 475:3–15 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jgb37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
74. Janas_010408 at 417 and 429:9–22 (the outline is DWRITE078142, available: http://dida.library.ucsf.edu/tid/rpc37b10); Janas_010408 at 432: 5–9 and DWRITE041313 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
75. DWRITE001151 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/hib37b10. Accessed 21 Aug 2009
76. DWRITE001154 [Internet] San Francisco Drug Industry Document Archive Available from: http://dida.library.ucsf.edu/tid/hic37b10. Accessed 21 Aug 2009. Also Janas 010408 at 487:19–22. Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 7 Feb 2010
77. DWRITE041522 (the Agreement with the University of Wisconsin) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jib37b10. Accessed 21 Aug 2009
78. DWRITE001138, DWRITE001140, DWRITE001143, DWRITE001149, and DWRITE001134 (Letters to authors from B. Janas regarding manuscripts for the April meeting) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
79. WarrenM
2004 A Comparative Review of the Risks and Benefits of Hormone Replacement Therapy Regimens. Am J Ob Gyn 190 4 1141 67
80. Supplement (Postmenopausal Hormone Therapy and Breast Health: A Review for Clinicians, October 2001, Supplement to Women's Health in Primary Care) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/yub37b10. Accessed 21 Aug 2009
81. DUROJ046-024195 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/gxc37b10. Accessed 21 Aug 2009
82. DUROJ046-024196 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/gyb37b10. Accessed 21 Aug 2009
83. Janas_010408 at 447:448 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
84. DWRITE078850 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/rtb37b10. Accessed 21 Aug 2009
85. Email communication with George Mejicano, Associate Dean for Continuing Professional Development, September 10, 2009
86. DWRITE001069 and DWRITE041522 at DWRITE041530 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jib37b10 and http://dida.library.ucsf.edu/tid/hdc37b10. Accessed 21 Aug 2009
87. DWRITE041522 at DWRITE041530, Janas_010408 at 420: 21–24 and 421: 1–12 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/jib37b10 and http://dida.library.ucsf.edu/tid/skc37b10. Accessed 21 Aug 2009
88. DUROJ017-001102 at DUROJ017-001103 (Publications Planning: Proactive Media Outreach) [Internet] San Francisco Drug Industry Document Archive Available from: http://dida.library.ucsf.edu/tid/fyc37b10. Accessed 7 Feb 2010
89. DWRITE001850, Janas_010408 415: 17–24 and DWRITE001079 at DWRITE001081 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu. Accessed 21 Aug 2009
90. DWRITE067764 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/mtc37b10. Accessed 21 Aug 2009
91. DWRITE067772 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/mxb37b10. Accessed 21 Aug 2009
92. DWRITE067766 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/mvb37b10. Accessed 21 Aug 2009
93. DWRITE067767 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/mvc37b10. Accessed 21 Aug 2009
94. DWRITE067768 [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/mwb37b10. Accessed 21 Aug 2009
95. HarrisG.
Document details plan to promote costly drug [Internet]. New York Times. 2009 Sep 2. Available: http://www.nytimes.com/2009/09/02/business/02drug.html. Accessed 4 Sept 2009
96. Lexapro FY04 marketing plan [Internet]. 2003 Apr 1. Available: http://www.nytimes.com/packages/pdf/politics/20090831MEDICARE/20090831_MEDICARE.pdf. Accessed 3 Sept 2009
97. PerroneM.
Glaxo used ghostwriting program to promote Paxil [Internet]. Associated Press. 2009 Aug 19. Available: http://www.sfgate.com/cgi- bin/article.cgi?f=/n/a/2009/08/19/national/w123616D16.DTL. Accessed 4 Sept 2009
98. McHenryL
2005 On the Origin of Great Ideas: Science in the Age of Big Pharma. Hastings Ctr Rep 35 6 17 19
99. McHenryL
JureidiniJ
2008 Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study. Accountability in Research 15 152 167
100. McHenryL
2010 Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine. Journalology 8 1 129 145
101. MundyA.
Dispensing with the Truth. 162 167 St Martins Press. New York: 2001
102. LandefeldCS
SteinmanMA
2009 The Neurontin legacy – marketing through misinformation and manipulation. NEJM 360 2 103 105
103. RossJosephS
HillKevinP
EgilmanDavidS
KrumholzHarlanM
2008 Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 299 15 1800 1812
104. HealyDavid
CattellDinah
2003 Interface between Authorship, Industry and Science in the Domain of Therapeutics. Br J Psych 183 22 27
105. FauberJ
KissingerM.
UW linked to ghostwriting [Internet]. Milwaukee Journal Sentinel. 2009 Aug 15. Available: http://www.jsonline.com/features/health/53315032.html. Accessed 18 Aug 2009
106. ArmstrongD
Wall Street Journal. Health Blog: WSJ's blog on health and the business of health [Internet]. Odd ghostwriting offer raises researcher's blood pressure New York Dow Jones & Company, Inc, c2009. 2007 Nov 21. Available: http://blogs.wsj.com/health/2007/11/21/odd-ghostwriting-offer-raises- researchers-blood-pressure/. Accessed 13 Feb 2009
107. SingerN.
Medical papers by ghostwriters pushed therapy [Internet]. New York Times. 2009 Aug 4. Available: http://www.nytimes.com/2009/08/05/health/research/05ghost.html. Accessed 4 Aug 2009
108. WilsonD.
Drug maker said to pay ghostwriters for journal articles [Internet]. New York Times. 2008 Dec 12. Available: http://www.nytimes.com/2008/12/12/business/13wyeth.html. Accessed 4 Aug 2009
109. CONTA025-031624 (Outline for Journal Supplement) [Internet] San Francisco Drug Industry Document Archive Available: http://dida.library.ucsf.edu/tid/bpb37b10. Accessed 21 Aug 2009
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2010 Číslo 9
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Co dělat při intoleranci statinů?
- Pleiotropní účinky statinů na kardiovaskulární systém
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
Najčítanejšie v tomto čísle
- Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?
- A Genetic Association Study of Serum Acute-Phase C-Reactive Protein Levels in Rheumatoid Arthritis: Implications for Clinical Interpretation
- Persistence with Statins and Onset of Rheumatoid Arthritis: A Population-Based Cohort Study
- Effectiveness of Chest Physiotherapy in Infants Hospitalized with Acute Bronchiolitis: A Multicenter, Randomized, Controlled Trial